StageBio has merged with Tox Path Specialists, LLC to create the leading provider of research and preclinical histology, pathology, specialized neuropathology, and archiving services for the biopharmaceutical, medical device and contract research industries. StageBio was recently created by the merger of Histo Scientific Research Laboratories and Vet Path Services and is a portfolio company of Ampersand Capital Partners.
“We are very excited to merge operations with Dr. Mark Butt and his team at Tox Path Specialists as we continue to broaden our service offerings to both new and existing clients,” said Tom Galati, StageBio CEO. “It is our intent to position StageBio as the most capable histopathology company in the industry.”
Dr. Mark Butt, Founder & CEO of Tox Path Specialists, commented, “StageBio and TPS are a natural fit. The broad spectrum of histopathology services of StageBio coupled with our specialty neuropathology capabilities are a great match and will further streamline the research process for our clients.” The merger adds laboratory space in Frederick, MD, and more importantly adds staff with vast experience in specialty neuropathology and techniques to complement the StageBio team based in Virginia, Ohio and Massachusetts. The combined business has over 20 board-certified pathologists and a total employee base of over 100.
Date: April 15, 2019
Source: Yahoo Finance